Shamburg News · 8-K filed Nov 13, 2026, 4:00 PM EST

Tonix Discloses Dr. Reddy's Paragraph IV ANDA Filing for Generic TONMYA and Patent Suit

TNXP · Tonix Pharmaceuticals Holding Corp.

  • Other event
  • Material agreement
  • Materiality: high

Tonix Pharmaceuticals Holding Corp. disclosed that on October 1, 2026 it received a notice from Dr. Reddy's Laboratories stating DRL filed an ANDA with a Paragraph IV certification for a generic version of TONMYA 2.8 mg sublingual tablets, citing U.S. Patent Nos. 9,636,408, 9,956,188, 10,117,936 and 10,864,175. On November 13, 2026 the Company filed a patent infringement complaint against DRL in the District of New Jersey. The filing states the complaint triggers a statutory stay of final FDA approval of the ANDA for up to 30 months, subject to exceptions and court orders.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 8.01, accession 0001493152-26-051693.

Written from the filing by Shamburg Markets. Figures are as reported by the company.